Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L21 pseudogene 32 (RPL21P32) is a processed pseudogene mapped to the human genome that shares sequence homology with the protein-coding RPL21 gene, which encodes a structural component of the ribosomal 60S subunit. Pseudogenes such as RPL21P32 are generally non-functional remnants of genes in the human genome and do not encode an active protein product. While some pseudogenes have been implicated in regulatory roles, there is currently no evidence that RPL21P32 has biological function, is relevant in disease, or serves as a therapeutic target. This distinguishes it from the parental RPL21 gene, which is functionally important in ribosome assembly and associated with diseases like hereditary hypotrichosis when mutated. RPL21P32 is therefore not a canonical drug target, receptor, enzyme, or disease biomarker.
None documented
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 32 (RPL21P32).